Device Trial Radar · NCT07920926
Hypothermic Kidney Machine Perfusion With Omnisol
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
May 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Vivalyx GmbHNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors. Preservation of DCD organs using the current clinically applied preservation solutions is associated with up to 73% incidence of delayed graft function, highlighting the need for new preservation solutions designed to improve early graft function. Omnisol is expected to result in equivalent or improved kidney preservation as compared to currently marketed organ preservation solutions used for HMP.
Conditions
- End Stage Renal Disease (ESRD)
- Kidney Transplant
- Kidney Failure
- Renal and Urinary Tract Therapeutic Procedures
Interventions
Omnisol organ preservation solutionDevice
Omnisol for HMP of DBD or DCD donors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Delayed Graft FunctionTime frame: 7 days post-transplantation.
1 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.